WILLIAM C. BRYSON, Circuit Judge.
Before the Court is the parties' Joint Motion to Seal Portions of the Trial Transcript (Dkt. No. 285). The motion is GRANTED IN PART and DENIED IN PART.
As a general matter, sealing judicial records, including the transcript of a trial or portions of the trial transcript, is contrary to the principle that judicial proceedings in this country are to be conducted in public. The Supreme Court has recognized the existence of a "general right to inspect and copy public records and documents, including judicial records and documents."
To be sure, the "right to inspect and copy judicial records is not absolute."
The decision whether to allow public access to court records is left to the "sound discretion of the trial court . . . to be exercised in light of the relevant facts and circumstances of the particular case."
The party seeking to seal court documents, including transcripts, has the burden of establishing that the presumption of public access to court records is overcome.
In this case, the parties have moved to seal significant portions of the trial transcript. The parties characterize the portions of the transcript that they wish to have sealed as "narrowly tailored excerpts." The Court, however, has carefully reviewed each of the nearly 100 portions of the transcript that the parties wish to have sealed, many of which include multiple pages, and is not persuaded that the excerpts are "narrowly tailored."
The materials identified by the parties fall into several general categories. Dr. Bianco's requests for sealing relate to (1) the details of the drawings that he provided to Globus in June 2007, and (2) information concerning Dr. Bianco's meeting with representatives of Biomet, another medical device manufacturer. Globus's requests for sealing relate to (1) the profits and profit margins on the Caliber and Rise lines of products, and (2) the royalty rates it paid to consulting surgeons who were members of Globus design teams on various projects.
In their joint motion, the parties have provided only a barebones explanation for why they believe sealing is necessary. The unelaborated characterizations of the materials they seek to have sealed read as follows: "Globus royalty rates, profit margins," "Globus royalty rates," "Globus royalty rates and margins," "Globus royalty rates and profit margins," "Dr. Bianco's testimony relating to his Invention Disclosure and his presentation to Biomet," "Mr. Rhoda's testimony relating to Dr. Bianco's Invention Disclosure," "Dr. McMillin's testimony relating to Dr. Bianco's Invention Disclosure," "Mr. Harris's testimony relating to Dr. Bianco's Invention Disclosure," "Mr. Ferreira's Deposition Transcript," "Dr. Cheng's testimony relating to Dr. Bianco's Invention Disclosure," and "Mr. Iott's testimony relating to Dr. Bianco's Invention Disclosure."
The absence of any elaboration could, by itself, be deemed a failure to "articulate compelling reasons supported by specific factual findings that outweigh the general history of access and the public policies favoring disclosure, such as the public interest in understanding the judicial process."
In those earlier pleadings, Dr. Bianco argued that the details of his invention disclosure to Globus should be sealed because the jury's verdict establishes that the disclosure is a trade secret. Trade secrets, Dr. Bianco argued, are among those materials that courts have been willing to protect from public disclosure by sealing court records. Dkt. No. 258, at 1-2. Globus argued that the public disclosure of nonpublic financial information related to its Caliber, Caliber-L, and Rise products—particularly the profits and profit margins on those products— would competitively harm Globus. Dkt. No. 259, at 2. And, according to Globus, release of information about Globus's royalty agreements with design team doctors "would grant Globus's competitors access as to details concerning the royalty percentages agreed to by Globus."
For the reasons given below, the Court concludes sealing is appropriate for certain portions of the transcript revealing details of Dr. Bianco's invention disclosure that are not disclosed elsewhere in the public record. Likewise, sealing is appropriate for very limited portions of the transcript relating to the nature of Dr. Bianco's presentation to Biomet. However, the Court concludes that sealing is not appropriate for the transcript excerpts relating to the royalty rates for Globus's design team doctors and to the profit margins for Globus's Caliber and Rise line of products.
1. At the outset, the Court notes that the force of the parties' request for sealing is undercut by the fact that they have failed to take appropriate measures to protect the material that they now wish to have sealed.
The trial in this case was held in open court; no request to close the courtroom was made at any time during the trial. Nor did the parties alert the Court at the time of trial that they objected to public disclosure of certain portions of the trial testimony. After the trial, in the course of a colloquy relating to the issue of sealing certain pleadings and orders, the Court pointed out that the trial had taken place in open court and the testimony at trial had all come in without any limitation on its public availability. The parties responded that they had kept track of the identity of those persons entering and leaving the courtroom, and that they were therefore confident that there was no significant risk that unknown third persons had obtained access to the sensitive information that was revealed in open court during the trial. The Court at that time expressed skepticism about the practical or legal effectiveness of such an informal method of protecting sensitive information and raised the question whether the parties had waived any right to have the trial proceedings sealed by not moving to close the courtroom during the presentation of sensitive information or requesting other protective measures.
Following that colloquy, the Court held an evidentiary hearing on future royalties. Once again, the parties did not ask to close the courtroom or to have sensitive materials otherwise protected, even though there was testimony at that hearing about the royalty rates paid to surgeons on Globus's design teams. Even if Globus can be excused for not having taken measures to close the trial proceedings when sensitive material was being discussed, it is difficult to understand why Globus would not seek some form of protection for the same material when it elicited that information from its own witnesses at the evidentiary hearing, which occurred after the problem of Globus's failure to seek courtroom closure during trial had been raised by the Court in connection with Globus's earlier sealing request.
Because the Court did not flag this issue for the parties prior to trial, the Court will not treat the parties' lax approach to the issue of protecting sensitive testimony from public disclosure as a waiver of their right now to seek sealing of the trial testimony. However, the Court regards the parties' failure to more actively protect the information elicited from witnesses in open court as an indication that the parties do not regard the materials at issue as highly sensitive.
2. A second problem with the parties' sealing request is that the substance of much of the information they seek to protect has already been publicly disclosed, either through filings that have not been sealed or in portions of the trial transcript that the parties have not moved to have sealed. For example, while Globus has requested sealing of various portions of the transcript dealing with the profits Globus has made on the Caliber and Rise line of products, it has not moved to seal a number of references that provide profit-related information. Those include allusions to Globus's royalty base profits of more than $100 million on Caliber and Rise (1/13/14 PM Tr. 10:6-12, 22:16-19; 1/15/14 AM Tr. 79:22-80:4), and net profits of $38.5 million (1/15/14 AM Tr. 46:6-12, 61:21-62-7, 77:17). In light of the public disclosure of those numbers, the Court discerns no protectable interest in the total sales of the Caliber and Rise products or the marginal profit percentages on those products, both of which Globus has sought to have sealed.
Moreover, Globus is a publicly traded company, and its sales and earnings are publicly reported. Because testimony at trial that Globus has not sought to have sealed reveals that the Caliber line of products accounted for between 10 and 16 percent of Globus's sales,
3. With respect to Dr. Bianco's sealing requests, the Court finds that the general nature of the drawings has been revealed in various public pleadings and orders. Accordingly, even though the jury found that the drawings are protected trade secrets, not all the details of the drawings are entitled to continued protection through a sealing order. Based on the jury's verdict as to the trade-secret status of the drawings, the Court is prepared to direct the sealing of portions of the trial testimony that consist of more detailed accounts of the drawings and reveal features that were not otherwise made public. The protection will not be extended to all the portions of the transcript requested by Dr. Bianco, however, because many of the transcript excerpts do not reveal any more than is already in the public record.
For example, the fact that Dr. Bianco regarded his drawings as depicting an adjustable interbody spacer with a scissor-jack mechanism has been a matter of public record since early in the case.
1/13/14 PM Tr.: 78:15-83:18; 99:3-21; 133:14-24.
1/14/14 AM Tr.: 178:18-185:14
1/14/14 PM Tr.: 72:3-73:11; 74:24-78:5; 120:15-121:1; 128:7-135:22, 150:3-151:1; 151:5-152:10; 154:6-155:2.
1/15/14 PM Tr.: 64:4-23; 140:7-141:17.
1/16/15 AM Tr.: 191:23-192:21.
1/16/14 PM Tr.: 5:24-6:24; 12:12-16:6.
1/17/14 AM Tr.: 59:9-16; 59:25-60:18.
4. Many of Globus's requests to seal particular portions of the transcript relate to the royalty rates paid to physicians on Globus's design teams for the Caliber and Rise products, as well as other products. The Court, however, is not persuaded that Globus has made a sufficiently compelling showing that those royalty rates are entitled to protection from disclosure. The evidence at trial showed that Globus's royalty rates for design team physicians are standard in the industry (1/16/14 PM Tr. 144:6-7), and Globus's standard rate is disclosed in at least one portion of the transcript for which Globus does not request sealing (1/16/14 PM Tr. 170:6-10).
Moreover, Andy Iott, Globus's senior vice-president for product development, testified at the evidentiary hearing on future royalties that it was his understanding that the royalty rates paid by Globus were typical of the rates paid to design team physicians by other companies in the field—rates that were not publicly disclosed by those companies but were generally known. 5/13/14 Tr. 106:14-107:6. Thus, the Court concludes that the testimony about the royalty rates to which Globus points would not reveal highly sensitive materials that would not otherwise be publicly known.
In the course of listing the portions of the trial transcript relating to its royalty rates, Globus includes references to a few royalty rates that were higher than the rates typically paid to design team physicians. Globus, however, has made no separate argument, much less introduced any evidence, to suggest that those enhanced royalty rates constitute highly sensitive commercial information that deserves the special protection accorded by a sealing order. The Court therefore will not order those portions of the transcript sealed.
5. Finally, the Court finds no merit in most of Dr. Bianco's requests to seal certain excerpts of the transcript relating to his 2013 presentation to Biomet. Much of the testimony to which Dr. Bianco points did not reveal confidential details of his presentation to Biomet, and thus revealed no trade secret or other protected information. Moreover, the general circumstances relating to Dr. Bianco's presentation to Biomet were revealed in both the opening statement and the closing argument of Globus, which Dr. Bianco has not sought to seal.
The Court will stay the effectiveness of this order for 10 days in the event that the parties wish to seek modification, reconsideration, or appellate review of the Court's decision on this matter.
IT IS SO ORDERED.